Details

Autor(en) / Beteiligte

• DeKoninck, Philip
• Toelen, Jaan
• Roubliova, Xenia
• Carter, Shea
• Pozzobon, Michela
• Russo, Francesca Maria
• Richter, Jute
• Vandersloten, Pieter-Jan
• Verbeken, Erik
• De Coppi, Paolo
• Deprest, Jan

Titel

The use of human amniotic fluid stem cells as an adjunct to promote pulmonary development in a rabbit model for congenital diaphragmatic hernia

Ist Teil von

• Prenatal diagnosis, 2015-09, Vol.35 (9), p.833-840

Ort / Verlag

England: Blackwell Publishing Ltd

Erscheinungsjahr

2015

Quelle

MEDLINE

Beschreibungen/Notizen

• What's already known about this topic? There is increasing evidence that cell therapy using mesenchymal stem cells could have a beneficial effect in treating adult lung disease. Amniotic fluid stem cells are a population of cells with multipotent differentiation capacities. Initial reports in rodent CDH models have shown promising evidence using these cells to improve pulmonary development in utero. What does this study add? Intra‐tracheal cell therapy with amniotic fluid stem cells in combination with tracheal occlusion in a rabbit CDH model increases the number of alveoli, without major signs of toxicity. Objective This study aimed to evaluate the potential benefit of intra‐tracheal injection of human amniotic fluid stem cells (hAFSC) on pulmonary development combined with TO in a rabbit model for CDH. Methods In time‐mated pregnant does a left diaphragmatic defect was created at d23 (term = 31). At d28, previously operated fetuses were assigned to either TO and injection with 70 μL of phosphate buffered saline (PBS) or 1.0 × 106 c‐Kit positive hAFSC expressing LacZ or were left untouched (CDH). Harvesting was done at d31 to obtain their lung‐to‐body weight ratio (LBWR), airway and vascular lung morphometry, X‐gal staining and immunohistochemistry for Ki67 and surfactant protein‐B (SP‐B). Results CDH‐induced pulmonary hypoplasia is countered by TO + PBS, this reverses LBWR, mean terminal bronchiole density (MTBD) and medial thickness to normal. The additional injection of hAFSC decreases MTBD and results in a non‐significant decrease in muscularization of intra‐acinary vessels. There were no inflammatory changes and LacZ positive hAFSC were dispersed throughout the lung parenchyma 4 days after injection. Conclusion HAFSC exert an additional effect on TO leading to a decrease in MTBD, a measure of alveolar number surrounding the terminal bronchioles, without signs of toxicity. © 2015 John Wiley & Sons, Ltd.